Difference between revisions of "Tafasitamab (Monjuvi)"
Jump to navigation
Jump to search
m (Jwarner moved page MOR208 to Tafasitamab (Monjuvi): FDA approval) |
m |
||
Line 5: | Line 5: | ||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
*[[Transformed lymphoma]] | *[[Transformed lymphoma]] | ||
− | |||
==History of changes in FDA indication== | ==History of changes in FDA indication== |
Revision as of 22:25, 3 August 2020
Mechanism of action
Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity
Diseases for which it is used
History of changes in FDA indication
- 7/31/2020: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.
Also known as
- Code names: MOR208, MOR00208, XmAb5574
- Generic name: tafasitamab-cxix
- Brand name: Monjuvi